Stock Track | METIS TECHBIO-P Soars 5.82% on Strategic AI Drug Development Alliance with Deerfield Management

Stock Track
06/01

METIS TECHBIO-P's stock price surged 5.82% intraday on Monday, driven by positive market reaction to a significant corporate development.

The sharp increase follows the company's announcement of a strategic alliance with the premier global health investment and innovation platform, Deerfield Management. The partnership is aimed at co-developing a new generation of in vivo protein therapeutics and immunotherapies, while jointly advancing the global commercialization of collaborative pipeline products.

Under the agreement, Deerfield will engage in in-depth collaboration on the global clinical development and commercial expansion initiatives related to METIS TECHBIO-P's proprietary AI-powered nano-delivery platform, NanoForge, and its core pipeline projects. This includes a leading T-cell engager project discovered by the company's in-house AiProtein platform.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10